Inhibitors of menin-mll interaction
AssigneeBiomea Fusion, Inc.
InventorsThomas BUTLER, Jim Palmer, Ravi Upasani, Matthew Welsch, Sridhar Vempati, Brendan Kelly, Edward Painter
Life of this patent
Estimating the term…
Abstract
Disclosed herein are heterocyclic compounds that inhibit the binding of menin and MLL or MLL fusion proteins. Also described are specific inhibitors of menin-MLL interaction. Also disclosed are pharmaceutical compositions that include the compounds. Methods of using the menin-MLL inhibitors are disclosed, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, leukemia and other diseases or conditions dependent on menin-MLL interaction.
Claims22
-104. (canceled)
A method for treating an autoimmune or heteroimmune disease or condition comprising administering to a patient in need thereof a therapeutically effective amount of a compound of formula (I):
- or a pharmaceutically acceptable salt thereof or pharmaceutical composition thereof, wherein:
- A is O, or N(R6a);
- Cy is
- wherein R7 is an optionally substituted group selected from a 4-7 membered heterocycloalkyl ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur, phenyl, an 8-10 membered bicyclic aryl ring, and a 5-6 membered heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur;
- one of X and Y is —NR3a—;
- and the other is —C(R3b)2—, —NR3b—, or —O—;
- R1 is an optionally substituted group selected from C1-6 alkyl, C3-7 cycloalkyl, phenyl, an 8-10 membered bicyclic aryl ring, a 4-7 membered heterocycloalkyl ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, or sulfur, and a 5-6 membered heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur;
- R2 is H, C1-6 alkyl, C1-6 haloalkyl, halo, or CN;
- each R3a, and R3b is independently H or C1-6 alkyl;
- each R4 is independently H, halo, CN, OR, —N(R)2, —C(O)N(R)2,
- —NRC(O)R, —SO2R, —C(O)R, —CO2R, or an optionally substituted group selected from C1-6 alkyl, C3-7 cycloalkyl, a 4-7 membered heterocycloalkyl ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, or sulfur, phenyl, an 8-10 membered bicyclic aryl ring, and a 5-6 membered heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur;
- each R is independently H, or an optionally substituted group selected from C1-6 aliphatic, phenyl, an 8-10 membered bicyclic aryl ring, a 4-7 membered saturated or partially unsaturated heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, or sulfur, and a 5-6 membered heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur, or:
- two R groups on the same nitrogen are taken together with their intervening atoms to form a 4-7 membered saturated, partially unsaturated, or heteroaryl ring having 0-3 heteroatoms, in addition to the nitrogen, independently selected from nitrogen, oxygen, or sulfur;
- R6a is H or and C1-6 alkyl;
- and
- n is 1, 2, 3, or 4.
Dependencies are inferred from the claim text.